Skip to main content
SpringerLink
Log in

Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia

  • Method
  • Published:
Pathology & Oncology Research

Abstract

Non-small cell lung cancer (NSCLC) represents 85 % of all malignant lung cancers. In metastatic disease the principle goal of palliative therapy is to prolong survival with least toxicity and best patients’ quality of life. Bevacizumab (BEV) has been approved as first line treatment in combination with platinum based chemotherapy and maintenance therapy in NSCLC. BEV can be added safely to several chemotherapeutic agents, however there is no data on coadministration with thermotherapy. Even in localized disease no robust evidence exists about the beneficial effect of loco-regional thermotherapy on overall survival, but it might be used successfully in symptom palliation. In this article a successful co-administration of BEV and hyperthermia is reported in a patient with monolocalized bone metastasis from previously operated NSCLC. This case suggests that electrohyperthermia can probably be incorporated in palliative therapy added not only to radiotherapy or chemotherapy but also to anti-angiogenic BEV treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Wakelee HA, Bernardo P, Johnson DH et al (2006) Changes in the natural history of nonsmall cell lung cancer (NSCLC)–comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer 06:2208–2217

    Article  Google Scholar 

  2. Yang P, Allen MS, Aubry MC et al (2005) Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 28:452–462

    Article  Google Scholar 

  3. Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539–4544

    Article  PubMed  Google Scholar 

  4. Azzoli CG, Baker S, Temin S et al (2009) American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for Stage IV non-Nmall-Cell Lung Cancer. J Clin Oncol 27:6251–6266

    Article  PubMed  CAS  Google Scholar 

  5. Sandler A, Gray R, Perry MC (2006) Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550

    Article  PubMed  CAS  Google Scholar 

  6. Reck M, von Pawel J, Zatloukal P (2009) Phase iii trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: avail. J Clin Oncol 27:1227–1234

    Article  PubMed  CAS  Google Scholar 

  7. Laskin J, Crinò L, Tsai C (2009) MO19390 (SAIL): first-line bevacizumab-based therapy in advanced non-small cell lung cancer (nsclc)—outcome by chemotherapy regimen [abstract C2.5]. J Thorac Oncol 4(Suppl 1):S359

    Google Scholar 

  8. Hirsh V (2008) Emerging safety data for bevacizumab in advanced non–small-cell lung cancer. Clin Lung Cancer 9(suppl 2):S62–S70

    Article  PubMed  Google Scholar 

  9. Crinò L, Mezger J, Griesinger F et al (2009) MO19390 (SAIL): safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (nsclc) [abstract 8043] Proc Am Soc. Clin Oncol 27:417s

    Google Scholar 

  10. Fischbach N, Spigel D, Brahmer J, on behalf of the ARIES investigators (2009) Preliminary safety and effectiveness of bevacizumab (bv) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (nsclc) from the aries study: a bevacizumab (bv) treatment observational cohort study (ocs) [abstract 8040]. Proc Am Soc Clin Oncol 27:416s

    Google Scholar 

  11. Mezger J, von Pawel J, Reck M (2009) Bevacizumab (Bv) single-agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (nsclc): results from an exploratory analysis of the avail study [abstract e19001] Proc Am Soc. Clin Oncol 27:e19001

    Google Scholar 

  12. Miller V, O’Connor P, Soh C, on behalf of the ATLAS Investigators (2009) A randomized, double-blind, placebo-controlled, phase iiib trial (atlas) comparing bevacizumab (b) therapy with or without erlotinib (e) after completion of chemotherapy with b for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (nsclc) [abstract LBA8002] Proc Am Soc. Clin Oncol 27:799s

    Article  Google Scholar 

  13. Hildebrandt B, Wust P, Ahlers O et al (2002) The cellular and molecular basis of hyperthermia. Clin Rev Oncol Haemat 43:33–56

    Article  Google Scholar 

  14. Jiang Z, Yan W, Ming J et al (2007) Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study. BMC Cancer 7:189

    Article  PubMed  Google Scholar 

  15. Shen H, Li XD, Wu CP et al (2011) The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: a phase II study. Int J Hyperthermia 27:27–32

    Article  PubMed  CAS  Google Scholar 

  16. Mitsumori M, Zeng ZF, Oliynychenko P et al (2007) Regional hyperthermia combined with radiotherapy for locally advanced non-small cell lung cancers: a multi-institutional prospective randomized trial of the International Atomic Energy Agency. Int J Clin Oncol 12:192–198

    Article  PubMed  Google Scholar 

  17. Moon SD, Ohguri T, Imada H et al (2011) Definitive radiotherapy plus regional hyperthermia with or without chemotherapy for superior sulcus tumors: a 20-year, single center experience. Lung Cancer 71:338–343

    Article  PubMed  Google Scholar 

  18. Sumiyoshi K, Strebel FR, Rowe RW et al (2003) The effect of whole-body hyperthermia combined with ‘metronomic’ chemotherapy on rat mammary adenocarcinoma metastases. Int J Hyperthermia 19:103–118

    Article  PubMed  CAS  Google Scholar 

  19. Hermisson M, Weller M (2000) Hyperthermia enhanced chemosensitivity of human malignant glioma cells. Anticancer Res 20(3A):1819–1823

    PubMed  CAS  Google Scholar 

  20. Szasz A, Szasz N, Szasz O (2010) Oncothermia –principles and practices. Springer Verlag, Heidelberg

    Google Scholar 

  21. Chun-Yi L, Yiing-Feng H, Hua-Tzu H et al (2009) Lung cancer with solitary bone metastasis in the radius. Clin Nucl Med 34:684–685

    Article  PubMed  Google Scholar 

  22. Shih WJ, Magoun S, Lahar B et al (1998) An unusual case of a tibial metastasis as the clinical presentation of bronchogenic adenocarcinoma. J Nucl Med Technol 26:91–93

    PubMed  CAS  Google Scholar 

  23. An SJ, Huang YS, Chen ZH (2011) et al. Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy, Med Oncol [Epub ahead of print]

    Google Scholar 

  24. Horn L, Dahlberg SE, Sandler AB et al (2009) Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 27:6006–6011

    Article  PubMed  CAS  Google Scholar 

  25. Herbst RS, Ansari R, Bustin F et al (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377:1846–1854

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institute of Oncology, Budapest, Hungary

    Gábor Rubovszky, Tünde Nagy, Mária Gődény & István Láng

  2. Biotechnics Department, Szt. István University, Gödöllő, Hungary

    András Szász

Authors
  1. Gábor Rubovszky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tünde Nagy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mária Gődény
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. András Szász
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. István Láng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gábor Rubovszky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rubovszky, G., Nagy, T., Gődény, M. et al. Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia. Pathol. Oncol. Res. 19, 119–122 (2013). https://doi.org/10.1007/s12253-012-9551-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-012-9551-7

Keywords

Search

Navigation